Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[124I]IB-PF-06687234
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[124I]IB-PF-06687234 is a radiolabeled version of PF-06687234, a fusion protein composed of a fully human single-chain variable fragment (scFv) antibody (F8, which targets extra-domain A of fibronectin selectively expressed in inflammatory tissue neovasculature), fused to the anti-inflammatory cytokine interleukin-10 (IL-10)[3][4][5]. The radiolabel [124I] (iodine-124) allows visualization by PET imaging of tissue distribution and targeting properties. PF-06687234 (F8IL10, Dekavil) is designed to deliver IL-10 specifically to inflamed tissues, thereby increasing local anti-inflammatory effects and reducing systemic toxicity, aiming to treat inflammatory bowel diseases such as ulcerative colitis[3][4][5]. The drug was developed by Pfizer under an exclusive license from Philogen[3][4]. Dekavil (F8IL10) is also being investigated in other indications, including rheumatoid arthritis[5].
- Brand names
- Dekavil
- Other names
- [124I]IB-PF-06687234[124I]-IODOBENZOYL-PF-06687234
02
Targets
IL10RA (Interleukin-10 Receptor)EDA (Extra domain A-fibronectin)
Beyond the preview
Go deeper on [124I]IB-PF-06687234.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [124I]IB-PF-06687234.